Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells

作者：Zhou, Ruoji; Xu, An; Tu, Jian; Liu, Mo; Gingold, Julian A.; Zhao, Ruiying^*; Lee, Dung-Fang^*

来源：Jove-Journal of Visualized Experiments, 2018, (136): e57664.

DOI：10.3791/57664

• Cancer Research
• Issue 136
• iPSCs
• Li-Fraumeni syndrome
• reprogramming
• differentiation
• mesenchymal stem cells
• osteoblasts
• osteosarcoma
• xenograft

Li-Fraumeni syndrome (LFS) is an autosomal dominant hereditary cancer disorder. Patients with LFS are predisposed to a various type of tumors, including osteosarcoma--one of the most frequent primary non-hematologic malignancies in the childhood and adolescence. Therefore, LFS provides an ideal model to study this malignancy. Taking advantage of iPSC methodologies, LFS-associated osteosarcoma can be successfully modeled by differentiating LFS patient iPSCs to mesenchymal stem cells (MSCs), and then to osteoblasts--the cells of origin for osteosarcomas. These LFS osteoblasts recapitulate oncogenic properties of osteosarcoma, providing an attractive model system for delineating the pathogenesis of osteosarcoma. This manuscript demonstrates a protocol for the generation of iPSCs from LFS patient fibroblasts, differentiation of iPSCs to MSCs, differentiation of MSCs to osteoblasts, and in vivo tumorigenesis using LFS osteoblasts. This iPSC disease model can be extended to identify potential biomarkers or therapeutic targets for LFS-associated osteosarcoma.

• 出版日期2018-6
• 单位中山大学